NovaGen Group
A Longevity Platform Built for Global Scale
NovaGen Group aims to change the trajectory of human ageing with treatments designed to restore immune function and slow age-related decline. Through proprietary science, data-driven client infrastructure, and a planned international network of regenerative longevity clinics, NovaGen is positioning itself to be a leader in a sector seeing rapid growth.
Bull case for NovaGen Group
A Global Platform Within a Huge Longevity Industry
Combination of a scalable clinic model, cell therapy and client data in a growing sector supported by ageing demographics and increasing awareness.
Clients Already Treated, with a Clear Path to Scale
Over 1,000 clients treated so far, while rivals valued in the billions have treated almost none.
Leading Science Run by World-Class Team of Experts
UCLA-derived research using a client's own cells, no gene editing, led by a top-cited scientist has potential to address several serious diseases.
Proposed Merger Brings a Nasdaq Listing and Further Health Technology
VEEA brings secure edge infrastructure that keeps health records, wearable data and biological readings under the client's own control.
Bear case for NovaGen Group
The Evidence Is the Company's Own
Reported results are exploratory and not independently verified, by NovaGen's own admission.
Formal Trials Are at an Early Stage
Only ALS has an approved trial, and it has yet to start.
The Listing Is Not Yet Finalised
The VEEA merger is still to complete.